Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1603 in moderate to severe systemic lupus erythematosus
ChiCTR2100054011Phase 2Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GR1603 in systemic lupus erythematosus (SLE) (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Safety evaluation index and Effectiveness evaluation index. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
GR1603
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2100054011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054011.